Skip to main content
Susanna Naggie, MD, Infectious Disease, Durham, NC

SusannaNaggieMDMHS

Infectious Disease Durham, NC

Associate Professor, Medicine, Duke University School of Medicine; Director, Infectious Disease Research, Duke Clinical Research Institute; Staff Physician, Durham VA Medical Center

Dr. Naggie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Naggie's full profile

Already have an account?

  • Office

    2100 Erwin Rd
    Durham, NC 27705
    Phone+1 919-684-8111

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Infectious Disease, 2007 - 2009
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2002 - 2005
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2002

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2002 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • What Ivermectin Can (And Can’t) Do
    What Ivermectin Can (And Can’t) DoMarch 31st, 2025
  • Asthma Drug Did Not Reduce Symptom Duration in Mild to Moderate COVID
    Asthma Drug Did Not Reduce Symptom Duration in Mild to Moderate COVIDOctober 22nd, 2024
  • Time to Sustained Recovery Among Outpatients with COVID-19 Receiving Montelukast vs Placebo
    Time to Sustained Recovery Among Outpatients with COVID-19 Receiving Montelukast vs PlaceboOctober 18th, 2024
  • Join now to see all

Grant Support

  • Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2026
  • Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
  • Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
  • Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
  • ACTIV-6DUKE UNIVERSITY2022–2025
  • ACTIV-6DUKE UNIVERSITY2022–2025
  • ACTIV-6DUKE UNIVERSITY2022–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • ACTIV-6DUKE UNIVERSITY2021–2025
  • Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
  • ACTIV-6DUKE UNIVERSITY2021–2025
  • Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
  • Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
  • Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
  • Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
  • Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
  • Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
  • Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
  • Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024